These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30012197)

  • 21. Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma.
    Both J; Krijgsman O; Bras J; Schaap GR; Baas F; Ylstra B; Hulsebos TJ
    PLoS One; 2014; 9(12):e115835. PubMed ID: 25551557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.
    Coco S; Theissen J; Scaruffi P; Stigliani S; Moretti S; Oberthuer A; Valdora F; Fischer M; Gallo F; Hero B; Bonassi S; Berthold F; Tonini GP
    Int J Cancer; 2012 Oct; 131(7):1591-600. PubMed ID: 22234802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis.
    Carlsson E; Krohn K; Ovaska K; Lindberg P; Häyry V; Maliniemi P; Lintulahti A; Korja M; Kivisaari R; Hussein S; Sarna S; Niiranen K; Hautaniemi S; Haapasalo H; Ranki A
    Genes Chromosomes Cancer; 2013 Feb; 52(2):191-201. PubMed ID: 23097141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk estimation of neuroblastoma patients using molecular markers.
    Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
    Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.
    Ohshima K; Hatakeyama K; Nagashima T; Watanabe Y; Kanto K; Doi Y; Ide T; Shimoda Y; Tanabe T; Ohnami S; Ohnami S; Serizawa M; Maruyama K; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
    Sci Rep; 2017 Apr; 7(1):641. PubMed ID: 28377632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The shaping and functional consequences of the dosage effect landscape in multiple myeloma.
    Samur MK; Shah PK; Wang X; Minvielle S; Magrangeas F; Avet-Loiseau H; Munshi NC; Li C
    BMC Genomics; 2013 Oct; 14():672. PubMed ID: 24088394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of Novel Genomic Markers for Predicting Prognosis in Hepatocellular Carcinoma Patients by Integrative Analysis of Copy Number Aberrations and Gene Expression Profiles: Results from a Long-Term Follow-Up.
    Cho HJ; Kim SS; Wang HJ; Kim BW; Cho H; Jung J; Cho SS; Kim JK; Lee JH; Kim YB; Yang MJ; Yoo BM; Lee KJ; Cho SW; Cheong JY
    DNA Cell Biol; 2016 Feb; 35(2):71-80. PubMed ID: 26624274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-resolution genomic and expression analyses of copy number alterations in breast tumors.
    Haverty PM; Fridlyand J; Li L; Getz G; Beroukhim R; Lohr S; Wu TD; Cavet G; Zhang Z; Chant J
    Genes Chromosomes Cancer; 2008 Jun; 47(6):530-42. PubMed ID: 18335499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
    Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Copy number alteration analysis for neuroblastoma using droplet digital polymerase chain reaction.
    Ishii Y; Sato-Otsubo A; Takita J; Morio T; Takagi M
    Pediatr Int; 2021 Oct; 63(10):1192-1197. PubMed ID: 33462952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic copy number alterations with transcriptional deregulation at 6p identify an aggressive HCC phenotype.
    Kwon SM; Kim DS; Won NH; Park SJ; Chwae YJ; Kang HC; Lee SH; Baik EJ; Thorgeirsson SS; Woo HG
    Carcinogenesis; 2013 Jul; 34(7):1543-50. PubMed ID: 23508637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
    Brady SW; Liu Y; Ma X; Gout AM; Hagiwara K; Zhou X; Wang J; Macias M; Chen X; Easton J; Mulder HL; Rusch M; Wang L; Nakitandwe J; Lei S; Davis EM; Naranjo A; Cheng C; Maris JM; Downing JR; Cheung NV; Hogarty MD; Dyer MA; Zhang J
    Nat Commun; 2020 Oct; 11(1):5183. PubMed ID: 33056981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-resolution array CGH profiling identifies Na/K transporting ATPase interacting 2 (NKAIN2) as a predisposing candidate gene in neuroblastoma.
    Romania P; Castellano A; Surace C; Citti A; De Ioris MA; Sirleto P; De Mariano M; Longo L; Boldrini R; Angioni A; Locatelli F; Fruci D
    PLoS One; 2013; 8(10):e78481. PubMed ID: 24205241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.
    Fieuw A; Kumps C; Schramm A; Pattyn F; Menten B; Antonacci F; Sudmant P; Schulte JH; Van Roy N; Vergult S; Buckley PG; De Paepe A; Noguera R; Versteeg R; Stallings R; Eggert A; Vandesompele J; De Preter K; Speleman F
    Int J Cancer; 2012 Jun; 130(11):2599-606. PubMed ID: 21796619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrative analysis based on survival associated co-expression gene modules for predicting Neuroblastoma patients' survival time.
    Han Y; Ye X; Cheng J; Zhang S; Feng W; Han Z; Zhang J; Huang K
    Biol Direct; 2019 Feb; 14(1):4. PubMed ID: 30760313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.
    Rosswog C; Schmidt R; Oberthuer A; Juraeva D; Brors B; Engesser A; Kahlert Y; Volland R; Bartenhagen C; Simon T; Berthold F; Hero B; Faldum A; Fischer M
    Neoplasia; 2017 Dec; 19(12):982-990. PubMed ID: 29091799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome-wide assessment of recurrent genomic imbalances in canine leukemia identifies evolutionarily conserved regions for subtype differentiation.
    Roode SC; Rotroff D; Avery AC; Suter SE; Bienzle D; Schiffman JD; Motsinger-Reif A; Breen M
    Chromosome Res; 2015 Dec; 23(4):681-708. PubMed ID: 26037708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
    Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
    Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data.
    Aure MR; Steinfeld I; Baumbusch LO; Liestøl K; Lipson D; Nyberg S; Naume B; Sahlberg KK; Kristensen VN; Børresen-Dale AL; Lingjærde OC; Yakhini Z
    PLoS One; 2013; 8(1):e53014. PubMed ID: 23382830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.